RxDoctor Payments Data

Maisie Burgess

Family · Metairie, LANPI 1083039044

Payments from drug & device makers

$6,457in general payments, 2019–2025

Across 334 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$1K
  • Johnson & Johnson$465
  • UCB, Inc.$385
  • Novartis$365
  • Mallinckrodt Hospital Products Inc.$347
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$6,437100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,457 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$8,358
Medicare patients
77
Services billed
157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib67$445,310
Humira(Cf) PenAdalimumab35$287,745
Enbrel SureclickEtanercept27$231,142
OtezlaApremilast25$126,089
Orencia ClickjectAbatacept12$70,394
Xeljanz XrTofacitinib Citrate11$66,240
KevzaraSarilumab15$65,484
ProliaDenosumab28$49,073
TymlosAbaloparatide12$32,010
Colchicine284$9,476
Hydroxychloroquine Sulfate304$8,913
MethotrexateMethotrexate Sodium411$6,800
Gabapentin303$4,718
Duloxetine Hcl187$3,835
Celecoxib222$3,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,211$445,31067 claims
AmgenOtezla, Prolia$1,141$175,16253 claims
SanofiKevzara$50$65,48415 claims
Radius Health, Inc.Tymlos$226$32,01012 claims
Scilex Pharmaceuticals Inc.Colchicine$40$9,476284 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.

Other family in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →